A US federal judge recently invalidated a Novartis AG patent on its transplantation medicine drug Zortress. Zortress is a prescription medicine (approved in 2010 and contains the generic ingredient everolimus) used to prevent transplant rejection in people who have received a kidney or liver transplant. The reason for the invalidation was that the judge found that this patent duplicated a patent which had already expired.
This result is obviously bad news for Novartis but good news for those seeking to sell the generic version of Zortress. Novartis has two other patents related to Zortress which were upheld following the judge’s ruling. Both of these patents will however expire in early 2018.